



MEMORANDUM

Prepared for: Oregon State Senate
Regarding: Review of Executive Appointments
Date: September 21, 2022

LPRO: LEGISLATIVE POLICY AND RESEARCH OFFICE

PRESCRIPTION DRUG AFFORDABILITY BOARD

The Governor has appointed the following individuals to the Prescription Drug Affordability Board, subject to Senate confirmation:¹

New Appointments

Amy Burns of Grants Pass
John Murray of Hepper

Term

09-28-2022 – 12-31-2024
09-28-2022 – 12-31-2024

Statutory Authority

[ORS 646A.693 \(2021\)](#).

Statement of Economic Interest²

Not required.

Composition³

The board consists of eight Oregon residents with expertise in clinical medicine and the economics of health care. Individuals employed by drug manufacturers or their trade associations are prohibited. There are five primary members and three alternates, serving staggered terms:

- terms for one member (**BURNS**) and one alternate (**MURRY**) end December 31, 2024;
- terms for two members (BRUNO and HARTUNG) and one alternate (SPAIN) end December 31, 2025; and
- terms for two members including the chair (BAILEY and PATTERSON) and one alternate (JUDGE) end December 31, 2026.

Subsequent appointees will serve four-year terms and all appointees are eligible for reappointment. A majority constitutes a quorum and the board is required to convene once every six weeks at minimum, so long as there are prescription drugs under review.

¹ [Or. Const. art. III, §4](#); [ORS 171.562](#) and [171.565 \(2021\)](#).

² [ORS 244.050 \(2021\)](#).

³ [ORS 646A.693 \(2021\)](#); see also [ORS 182.100 \(2021\)](#) for affirmative action policy and [ORS 236.115 \(2021\)](#) for diversity criteria.

Duties⁴

The board is tasked with evaluating the prescription drug distribution and payment system statewide, in its entirety, as well as policies in other jurisdictions that aim to lower prescription drug list prices, and make recommendations to the legislature by December 31, 2022.

The board must also:

- identify at least nine drugs and one insulin product annually as specified that it determines will pose cost challenges for patients or health care systems;
- report to the legislature and the Health Care Cost Growth Target program annually as specified, on price trends and drugs that were reviewed; and,
- study the national market for generic drugs as specified and report to the legislature annually.

⁴ [ORS 646A.694 \(2021\) to 616A.697 \(2021\)](#) and [Section 7, chapter 598, Oregon Laws 2021](#).

Executive Appointments Board Roster

Prescription Drug Affordability Board

Agency: Consumer & Business Services
Authorization: 646A.693; SB 844 (2021)
Members: Min: 5 Max: 8
Term Length: 4 years Limit: None
Senate confirmation required? Yes

Policy Area: Health

Board Contact:
Ralph Magrish

Ralph.M.MAGRISH@dcbs.oregon.gov

Current Appointments:

Member Name and Address (Alphabetical)

Shelley Bailey Primary Member Term(s): 06-10-2022 - 12-31-2026	Position Number: 2
--	--------------------

Richard Bruno Primary Member Term(s): 06-10-2022 - 12-31-2025	Position Number: 3
---	--------------------

Amy M Burns Primary Member Term(s): 09-28-2022 - 12-31-2024	Position Number: 5
---	--------------------

Daniel Hartung Primary Member Term(s): 06-10-2022 - 12-31-2025	Position Number: 4
--	--------------------

Robert M Judge Alternate Member Term(s): 06-10-2022 - 12-31-2026	Position Number: 6
--	--------------------

John Murray Alternate Member Term(s): 09-28-2022 - 12-31-2024	Position Number: 8
---	--------------------

Akil Patterson Primary Member Term(s): 06-10-2022 - 12-31-2026	Position Number: 1
--	--------------------

Rebecca Spain Alternate Member Term(s): 06-10-2022 - 12-31-2025	Position Number: 7
---	--------------------